Stockreport

Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity

Altimmune, Inc.  (ALT) 
NASDAQ:AMEX Investor Relations: altimmune.com/investors
PDF Company and Agency aligned on key efficacy and safety measures to be studied in Phase 3 program Pivotal Phase 3 trials designed to leverage the differentiated attribu [Read more]